Docetaxel and Erlotinib in Treating Older Patients With Prostate Cancer
Status:
Completed
Trial end date:
2008-03-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop
tumor cells from dividing so they stop growing or die. Erlotinib may stop the growth of tumor
cells by blocking the enzymes necessary for their growth. Combining docetaxel with erlotinib
may kill more tumor cells.
PURPOSE: This phase II trial is studying how well giving docetaxel together with erlotinib
works in treating older patients with progressive prostate cancer that has not responded to
hormone therapy.
Phase:
Phase 2
Details
Lead Sponsor:
Jonsson Comprehensive Cancer Center
Collaborators:
Aventis Pharmaceuticals Genentec National Cancer Institute (NCI)